Several products liability attorneys say that the recent appearance of lawsuits nationwide against the manufacturers of testosterone therapy drugs indicates the potential for multidistrict litigation and possibly a new mass tort.
Many of the current suits filed in federal courts across the country are against Abbott Laboratories—maker of the topical testosterone therapy drug AndroGel—which lawyers say has been the dominant producer of testosterone therapy drugs on the market.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
